Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial

@article{Hinks2021AzithromycinVS,
  title={Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial},
  author={Timothy S. C. Hinks and Lucy Cureton and Ruth Knight and Ariel Wang and Jennifer L. Cane and Vicki S Barber and Joanna Black and Susan J Dutton and James Melhorn and Maisha F. Jabeen and Phil Moss and Rajendar Garlapati and Tanya Baron and Graham Johnson and Fleur Cantle and David Clarke and Samer Elkhodair and Jonathan Underwood and Daniel S Lasserson and Ian D. Pavord and Sophie B. Morgan and Duncan B. Richards},
  journal={The Lancet. Respiratory Medicine},
  year={2021},
  volume={9},
  pages={1130 - 1140}
}

Figures and Tables from this paper

Azithromycin use and outcomes in patients with COVID-19: an observational real-world study

Azithromycin in patients with COVID-19: a systematic review and meta-analysis

The results presented in this systematic review and meta-analysis do not support the use of azithromycin in the management of CO VID-19 and future research on treatment for patients with COVID-19 may need to focus on other drugs.

Outcomes of patients with severe and critical COVID-19 treated with dexamethasone: a prospective cohort study

Treatment with corticosteroids was associated with reduced in-hospital mortality among patients with severe and critical COVID-19, including those on IMV, and CS-T was independently associated with lower mortality.

Failed clinical trials on COVID-19 acute respiratory distress syndrome in hospitalized patients: common oversights and streamlining the development of clinically effective therapeutics

Future clinical trials should be designed to standardize clinical approaches, with appropriate organization, patient selection, addition of control groups, and careful identification of disease phase to reduce heterogeneity and bias and should rely on the integration of scientific societies to promote a consensus on interpretation of the data and recommendations for optimal COVID-19 therapies.

Comparative effectiveness of pharmacological interventions on mortality and the average length of hospital stay of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials

Mortality and the average length of hospital stay of COVID-19 patients were significantly reduced with anti-inflammatory drugs, and no effectiveness was found in other pharmacological interventions.

Antibiotic Use and Bacterial Infection in COVID-19 Patients in the Second Phase of the SARS-CoV-2 Pandemic: A Scoping Review

The antibiotic prescribing rate for COVID-19 patients (June 2020–March 2021) was found to have declined overall, and the most frequently prescribed antibiotics were all on the “Watch” list of the WHO AWaRe antibiotics classification.

Early Outpatient Treatment of COVID-19: A Retrospective Analysis of 392 Cases in Italy

The use of individual drugs and drug combinations described in this study appears effective and safe, as indicated by the few and mild ADR reported, and the effectiveness and safety of COVID-19 early treatment in the real world.

Host‐modifying drugs against COVID‐19: some successes, but not yet the breakthrough

  • H. Brüssow
  • Medicine, Biology
    Environmental microbiology
  • 2021
The trials showed a clear need for new drugs instead of repurposed drugs and drugs that specifically target the SARS‐CoV‐2 virus or the pathology developing in COVID‐19 patients.

COVID-19 Patient Management in Outpatient Setting: A Population-Based Study from Southern Italy

The drug prescribing patterns for CO VID-19 treatment in an outpatient setting from Southern Italy was not supported from current evidence on beneficial therapies for early treatment of COVID-19, thus highlighting the need to implement strategies for improving appropriate drug prescribing in general practice.

Antidepressants for COVID-19: A systematic review

References

SHOWING 1-10 OF 33 REFERENCES

Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial

  • Christopher C Jienchi Ly-Mee Oghenekome Gail Benjamin R Oliver Butler Dorward Yu Gbinigie Hayward Saville Van HecC. Butler F. Hobbs
  • Medicine
    The Lancet
  • 2021

A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care in ambulatory COVID-19: study protocol for the ATOMIC2 trial

This trial will determine the clinical utility of azithromycin in patients with moderately severe, clinically diagnosed COVID-19 and could be rapidly applicable worldwide.

Hydroxychloroquine versus Azithromycin for Hospitalized Patients with COVID-19. Results of a Randomized, Active Comparator Trial

The results are consistent with conclusions from other trials that hydroxychloroquine cannot be recommended for inpatients with COVID-19; azithromycin may merit additional investigation.

Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19

Among patients hospitalized with mild-to-moderate Covid-19, the use of hydroxychloroquine, alone or with azithromycin, did not improve clinical status at 15 days as compared with standard care.

A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19

In hospitalized adult patients with severe Covid-19, no benefit was observed with lopinavir–ritonavir treatment beyond standard care, and future trials in patients withsevere illness may help to confirm or exclude the possibility of a treatment benefit.

A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19

Monoclonal antibody LY-CoV555, when coadministered with remdesivir, did not demonstrate efficacy among hospitalized patients who had Covid-19 without end-organ failure.